EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Photothermal Therapy-Induced Immunogenic Cell Death Synergistically Enhances the Therapeutic Effect of Immune Checkpoint Inhibitors

Shogo Yasuda iD, Yui Horikawa, Mei Ohashi, Mai Amou, Taisei Kanamori, Duan Runjing, Yuta Tamemoto iD, Wei Xu iD, Takuro Niidome iD, Akihiro Hisaka iD, Hiroto Hatakeyama iD

Cancers · 16.01.2026 · 18 (2) · 287

DOI: 10.3390/cancers18020287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 16.01.2026. Verfasst von Shogo Yasuda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-City 260-8…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicine CHIBA Doctoral WISE Program (iMeC-WISE), the Institute for Global Prominent Research at Chiba University, Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: To improve the response rate of immune checkpoint inhibitors (ICIs), inducing immunogenic cell death (ICD) is a promising approach. Photothermal therapy (PTT) induces immunogenic cell death and activates anti-tumor immunity. While there are various ICD inducers, the difference in ICD induction by various modalities is poorly understood. In this study, we found previously unrecognized advantages of PTT compared to anti-cancer drugs and showed the usefulness of PTT as an anti-cancer drug-free approach to be combined with immunotherapy.

Methods

Gold nanorods were synthesized as photothermal agents and added to culture medium or locally administered to tumor tissues. Mitoxantrone (MIT), an ICD inducer, and cisplatin (CDDP), a non-ICD inducer, were compared with PTT. To assess the induction of ICD, the subcellular localization and amounts of high mobility group box 1 (HMGB1) and calreticulin (CRT) were observed using immunofluorescent staining. FM3A tumor-bearing mice were treated with PTT or anti-cancer drugs, and cell death and DAMPs localization in tumor tissues were analyzed. Also, the supra-additive effect of PTT on ICI was observed. Tumor-infiltrating CD8+ T cells were examined to evaluate the immune status in tumor tissues.

Results

In vivo assays showed that PTT induces HMGB1 release and increased expression of CRT on the cell membrane. Moreover, PTT showed a supra-additive effect in terms of therapeutic effect and anti-tumor activation when combined with an immune checkpoint inhibitor.

Conclusions

In this study, we demonstrated that PTT induced ICD-related signaling and improved the response rate of ICI, which means PTT is a promising combination therapy with ICI.

Schlagwörter

Stichwörter der Autor:innen

damage-associated molecular patternsimmune checkpoint inhibitorimmunogenic cell deathphotothermal therapy

Autor:innen und Institutionen

  • Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-City 260-8675, Chiba, Japan.
  • Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-City 260-8675, Chiba, Japan.
  • Faculty of Advanced Science and Technology, Kumamoto University, 2-39-1 Kurokami, Chuo-ku, Kumamoto-City 860-8555, Kumamoto, Japan.
  • Center of Quantum Life Science for Structural Therapeutics (cQUEST), Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba-City 263-8522, Chiba, Japan.

ORCID-Profile: Shogo Yasuda, Yuta Tamemoto, Wei Xu, Takuro Niidome, Akihiro Hisaka, Hiroto Hatakeyama

Förderung

  • Innovative Medicine CHIBA Doctoral WISE Program (iMeC-WISE)
  • the Institute for Global Prominent Research at Chiba University
  • Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan
  • JSPS KAKENHI
  • Astellas Foundation for Research on Metabolic Disorders
  • the Takeda Science Foundation
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • the Uehara Memorial Foundation

Zitieren

APA

Yasuda, S., Horikawa, Y., Ohashi, M., Amou, M., Kanamori, T., Runjing, D., Tamemoto, Y., Xu, W., Niidome, T., Hisaka, A., & Hatakeyama, H. (2026). Photothermal Therapy-Induced Immunogenic Cell Death Synergistically Enhances the Therapeutic Effect of Immune Checkpoint Inhibitors. Cancers, 18(2), 287. https://doi.org/10.3390/cancers18020287

Vancouver

Yasuda S, Horikawa Y, Ohashi M, Amou M, Kanamori T, Runjing D, et al. Photothermal Therapy-Induced Immunogenic Cell Death Synergistically Enhances the Therapeutic Effect of Immune Checkpoint Inhibitors. Cancers. 2026;18(2):287. doi:10.3390/cancers18020287

BibTeX
@article{Yasuda2026,
  author = {Yasuda, Shogo and Horikawa, Yui and Ohashi, Mei and Amou, Mai and Kanamori, Taisei and Runjing, Duan and Tamemoto, Yuta and Xu, Wei and Niidome, Takuro and Hisaka, Akihiro and Hatakeyama, Hiroto},
  title = {Photothermal Therapy-Induced Immunogenic Cell Death Synergistically Enhances the Therapeutic Effect of Immune Checkpoint Inhibitors},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {2},
  pages = {287},
  doi = {10.3390/cancers18020287}
}
Kostenlos starten →